Posted by Michael Wonder on 03 Dec 2015
GSK receives European marketing authorisation for Nucala (mepolizumab) in 31 countries
2 December 2015 - Nucala is the first anti-IL-5 treatment for patients with severe refractory eosinophilic asthma in the EU.
For more details, go to: https://www.gsk.com/en-gb/media/press-releases/2015/gsk-receives-european-marketing-authorisation-for-nucala-mepolizumab-in-31-countries/
